In conclusion, our analysis reveals substantial variability in GLP-1 RA responses in individuals with type 2 diabetes in routine clinical practice, with only a minority of individuals achieving both glycaemic and weight reductions in the first 6 months of treatment
Putting my optimistic hat on, I want to call out the awesome progress that we (patients, regulators, patient advocates, employers, providers, health systems, government) have made over the last few years
However, on April 21, CMS announced it would delay the BALANCE Model for Medicare beneficiaries because it had not secured sufficient commitments from Part D insurers
None of this compromised the medication, but for an injectable prescription, presentation matters